Search results

From a Nursing Times article from March 2024: [url unfurl=false]https://www.nursingtimes.net/workforce/me-services-in-dire-state-after-death-of-specialist-nurse-05-03-2024/[/url]

In the "delivery plan" they committed to exploring it, no more: [url unfurl=false]https://www.gov.uk/government/publications/mecfs-the-final-delivery-plan/myalgic-encephalomyelitischronic-fatigue-syndrome-mecfs-the-final-delivery-plan[/url] Is there any reason to be hopeful that AfME's...

News story from today: [url unfurl=false]https://www.bbc.co.uk/news/articles/cp37g3xkwdgo[/url] What treatment?

This is part of a series of papers relating to the future of the DSM in the American Journal of Psychiatry. The others: The Future of DSM: Role of Candidate Biomarkers and Biological Factors The Future of DSM: A Report From the Structure and Dimensions Subcommittee The Future of DSM: A...

Haven't had the opportunity to read through but, in my search alerts today, there was a link to a new book written by a health journalist about ME/CFS in the German media. For those with access it is downloadable via SpringerLink. [url unfurl=false]https://doi.org/10.1007/978-3-658-50566-0[/url]

Do you get any sense that any of the charities & advocacy organisations involved in the process understand the fundamental problems with current NHS provision - i.e. the current network of psychobehavioural clinics - or are they essentially all on the same side as BACME on this?

On a very quick skim this seems thoughtful and apposite. My only disagreement with the authors would be whether we need any of these terms - whether "neuroinflammation", or novel ones like "neuroimmune alterations" or "altered neuroimmune activity" - at all. If (say) altered TSPO expression is...

Population-scale sequencing resolves determinants of persistent EBV DNA (Nature, 28 January 2026) ___ Scraps of viral DNA in biobank samples reveal secrets of Epstein–Barr virus (Nature News) This virus infects most of us – but why do only some get very ill? (New Scientist)

Correspondence in J Psychosom Res regarding this paper: Distress in POTS is largely driven by ineffective healthcare, not patients' attitudes A few quotes:

It's pretty hard, in this era of Google and ChatGPT, to hide the fact that an antidepressant is an antidepressant from even adolescent patients - not to mention that I haven't seen any positive results from robust trials of serotoninergics in this patient population. And that the...

Not sure this framing is particularly helpful: And then there's this: So close, yet so far.

Probably doesn't need its own thread but curious to see this letter in the Journal of Psychosomatic Research: Distress in POTS is largely driven by ineffective healthcare, not patients' attitudes (Blitshteyn & Grubb)

While his behind-the-scenes involvement with NICE would not surprise me I do not think the redactions are SW specific. If you look at e.g. the second consultation responses document on this page (link) there are other names redacted as well - there seems to have been a general policy of...

Abstract: In this article, we have reviewed the literature on severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ME/CFS is a clinical diagnosis in the absence of a diagnostic test. However, in research settings and disability disputes, 2-day cardiopulmonary exercise testing can...

There is also more recent work describing ZNFX1's ubiquitin ligase activity - A split-site E3 ligase mechanism enables ZNFX1 to ubiquitinate and cluster single-stranded RNA into ubiquitin-coated nucleoprotein particles also of relevance: ZNFX1 antisense RNA1 promotes antiviral innate immune...

Yes. From what I've been able to discern there are a few (mostly private) gastroenterologists & neurogastroenterologists in the UK in what might be called the EDS-III orbit who do seem to give out questionable gastroparesis diagnoses to patients who might ordinarily be diagnosed with e.g. IBS -...

This is, I think, the Sykes paper on the "functional" term & psychogenicity: [url unfurl=false]https://philpapers.org/rec/SYKFRN[/url]

(LC_AM is the LC after mild-moderate COVID group; LC_AS is the LC after severe acute COVID group.)

Haven't yet looked at the paper itself but noticed there was a useful (and perhaps more accessible) article in Nature Immunology's news section summarising it: Immunologically distinct long COVID after mild acute disease